Abstract: Disclosed are a sublingual film dosage of Rasagiline or a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof. The sublingual film dosage comprises the following prescription components: 0.5%-15% of Rasagiline or a pharmaceutically acceptable salt thereof, 30%-85% of a high molecular film forming material, 5%-40% of a dextrin, 0%-30% but not 0% of other excipients. The dextrin is one or more of maltodextrin, hydroxypropyl-?-cyclodextrin, glucosyl-?-cyclodextrin and sulfobutyl-?-cyclodextrin. The percentage is the mass percentage of each component relative to the total prescription components of the sublingual film dosage, respectively.

Abstract: An enteric formulation of duloxetine, its core and preparing method thereof are disclosed. The core comprises duloxetine or its salt and pharmaceutically acceptable excipients. The excipients include water-soluble hot melt materials selected from PEG, poloxamer, polyoxyl (40) stearate or their mixture. Based on the total weight of the core, the amount of water-soluble hot melt materials is 10%˜40% and the amount of duloxetine or its salt is 15˜60%. The core material is prepared by hot melt process. The enteric formulation comprises the core, a separating layer and an enteric layer.

Abstract: An enteric formulation of duloxetine, its core and preparing method thereof are disclosed. The core comprises duloxetine or its salt and pharmaceutically acceptable excipients. The excipients include water-soluble hot melt materials selected from PEG, poloxamer, polyoxyl (40) stearate or their mixture. Based on the total weight of the core, the amount of water-soluble hot melt materials is 10%˜40% and the amount of duloxetine or its salt is 15˜60%. The core material is prepared by hot melt process. The enteric formulation comprises the core, a separating layer and an enteric layer.